Advancing Care for Patients With Small-Cell Lung Cancer – An In The Clinic Activity




This activity is provided by Integrity Continuing Education, Inc.


This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.


Small-cell lung cancer (SCLC) is an aggressive disease that is associated with early metastasis and a high recurrence rate. Patients with platinum-sensitive disease have a better prognosis than those who relapse/recur while on 1st-line treatment or soon after. Since the majority of patients will experience recurrence, monitoring for recurrence and planning for 2nd-line treatment at diagnosis is necessary, but less than 50% of patients who experience recurrence will go on to receive 2nd-line treatment.

Dr. Narjust Florez will lead our faculty, Drs. Rodriquez and Smith, through a case discussion in which they will highlight their own treatment approaches for this difficult-to-treat patient population.


Narjust Duma Florez, MD
Associate Director of Cancer Care Equity
Thoracic Oncologist
Dana-Farber Cancer Institute
Boston, Massachusetts

Estelamari Rodriguez, MD, MPH
Associate Director of Community Outreach
Thoracic Oncology Division
Sylvester Comprehensive Cancer Center
University of Miami Miller School of Medicine
Miami, Florida

Cardinale Smith, MD, PhD
Department of Hematology/Oncology
Icahn School of Medicine
New York, New York


Shruti Rajesh Patel, MD
Department of Oncology
Stanford Health Care
Stanford, California

Release date: November 15, 2022
Expiration date: November 15, 2023
Estimated time to complete activity: 45 minutes

This educational initiative has been designed for medical and surgical oncologists, pulmonologists, and oncology physician assistants, nurse practitioners, and nurses.


Upon completion of this educational activity, participants should be able to:

  • Select optimal therapy for patients with SCLC based on patient and disease characteristics
  • Identify strategies to manage or mitigate treatment-related side effects of 2nd-line therapy for SCLC
  • Identify the benefits of early utilization of palliative care in patients with SCLC

There are no fees for participating and receiving CME credit for this activity. During the period of November 15, 2022 through November 15, 2023, participants must:

  • Read the learning objectives
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 100%.




Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or


Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Narjust Duma Florez, MD
Consultant/Advisor: Pfizer
Diversity and Inclusion Consultant: AstraZeneca, Bristol Myers Squibb Oncology, Daiichi Sankyo, Janssen, Merck
Tumor Board Lead: Neogenomics

Shruti Rajesh Patel, MD has no real or apparent conflicts of interest to disclose.

Estelamari Rodriguez, MD, MPH
Consultant: AstraZeneca, Bristol Myers Squibb, Eli Lilly, Genentech, Janssen Oncology
Speaker: Bristol Myers Squibb, Celgene, Janssen, Takeda

Cardinale Smith, MD, PhD
Research: Bristol Myers Squibb
Speaker: AstraZeneca

The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)


Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Continue to Pretest